Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunologic diagnosis kit for detecting type II dengue virus NS1 antigen

A dengue virus and immunodiagnosis technology, applied in the field of dengue virus detection kits, can solve the problem of dengue virus that cannot distinguish four serotypes, etc.

Active Publication Date: 2008-07-23
SOUTHERN MEDICAL UNIVERSITY
View PDF0 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, the kit cannot distinguish between the four serotypes of dengue virus, because the clinical symptoms caused by different serotypes of dengue virus infection are different, clinicians must determine which serotype of dengue virus infection as early as possible , in order to take effective treatment measures quickly, therefore, it is necessary to determine the type of dengue virus infected in time, and this kit cannot achieve this purpose

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunologic diagnosis kit for detecting type II dengue virus NS1 antigen
  • Immunologic diagnosis kit for detecting type II dengue virus NS1 antigen
  • Immunologic diagnosis kit for detecting type II dengue virus NS1 antigen

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0017] 1. The kit of the present invention consists of the following reagents:

[0018] (1) Microwell reaction plate coated with monoclonal antibody DV2-M6;

[0019] (2) Sample treatment solution: composed of sample treatment solution A and sample treatment solution B, wherein A is a 1.5M glycine solution (PH2.8), and B is a 1.5M Tris-Hcl solution (PH9.7);

[0020] (3) Biotin-labeled monoclonal antibody DV2-M14;

[0021] (4) horseradish peroxidase-labeled avidin, purchased from Zymed Company;

[0022] (5) Concentrated lotion: 20×PBS containing 2% Tween-20, that is, 4.56g NaH in 1L solution 2 PO 4 , 58.02gNa 2 HPO 4 .12H 2 O, 175.3gNaCl, 15 lbs, 20min autoclave, add 20ml Tween-20, stir well, dilute 20 times when used;

[0023] (6) Positive control: 1:1000 dilution of DV2NS1 antigen;

[0024](7) Negative control: 10mM PH7.4PBS containing 0.1% Tween-20, that is, 4.56gNaH in 1L solution 2 PO 4 , 58.02g Na 2 HPO 4 .12H 2 O, 175.3g NaCl, 15 pounds 20min autoclave, add 0...

example 2

[0091] 1. The kit of the present invention consists of the following reagents:

[0092] (1) Microwell reaction plate coated with monoclonal antibody DV2-M6;

[0093] (2) Composed of sample treatment solution A and sample treatment solution B, wherein A is a 1.5M glycine solution (PH2.8), and B is a 1.5M Tris-Hcl solution (PH9.7);

[0094] (3) Mab DV2-M14 labeled with horseradish peroxidase;

[0095] (4) Concentrated lotion: 20×PBS containing 2% Tween-20, that is, 4.56g NaH in 1L solution 2 PO 4 , 58.02gNa 2 HPO 4 .12H 2 O, 175.3g NaCl, 15 pounds of 20min after autoclaving, add 20ml Tween-20 and stir well, dilute 20 times when used;

[0096] (5) Positive control: 1:1000 dilution of DV2NS1 antigen;

[0097] (6) Negative control: 10mM PH7.4PBS containing 0.1% Tween-20, that is, 4.56g NaH in 1L solution 2 PO 4 , 58.02g Na 2 HPO 4 .12H 2 O, 175.3g NaCl, 15 pounds 20min autoclave, add 0.1% Tween-20 after 20-fold dilution;

[0098] (7) Chromogenic solution: It is compose...

example 3

[0109] 1. The kit of the present invention consists of the following reagents:

[0110] (1) Microwell reaction plate coated with monoclonal antibody DV2-M6;

[0111] (2) Sample treatment solution: composed of sample treatment solution A and sample treatment solution B, wherein A is a 1.5M glycine solution (PH2.8), and B is a 1.5M Tris-Hcl solution (PH9.7);

[0112] (3) Alkaline phosphatase-labeled monoclonal antibody DV2-M14;

[0113] (4) Concentrated lotion: 20×PBS containing 2% Tween-20, that is, 4.56g NaH in 1L solution 2 PO 4 , 58.02gNa 2 HPO 4 .12H 2 O, 175.3g NaCl, 15 pounds of 20min after autoclaving, add 20ml Tween-20 and stir well, dilute 20 times when used;

[0114] (5) Positive control: 1:1000 dilution of DV2NS1 antigen;

[0115] (6) Negative control: 10mM PH7.4PBS containing 0.1% Tween-20, that is, 4.56g NaH in 1L solution 2 PO 4 , 58.02g Na 2 HPO 4 .12H 2 O, 175.3g NaCl, 15 pounds 20min autoclave, add 0.1% Tween-20 after 20-fold dilution;

[0116] (7)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an immunity diagnosis test kit for detecting II-type dengue virus antigen, which comprises a porous reaction plate covering monoclonal antibody DV2-M6, a sample treatment liquid, a monoclonal antibody DV2-M15 marked with a label, a positive contrast, a negative contrast, a concentration washing liquid, a develop liquid and a termination liquid, wherein the monoclonal antibodies DV2-M6 and DV2-M14 of the test kit can be specifically combined with NS1 protein of II-type dengue virus, without cross reaction with other three kinds of serotype dengue viruses NS1 and respectively combined with different antigen points of NS1, while the check sensitivity of NS1 protein of II-type dengue virus can reach 3ng / ml and the check sensitivity of culture supernatant of II-type dengue virus infection cell is 8 power of Pan-E dengue early elisa test kit, thereby improving the sensitivity of clinical serum sample check.

Description

technical field [0001] The invention relates to a medical preparation, in particular to a kit for detecting dengue virus. Background technique [0002] Over the past half century, some mosquito-borne diseases, especially dengue fever, caused by dengue virus, have been reduced due to the significant increase in tourism and trade, changes in the ecological environment, global population growth and concentration in cities, and global warming. And dengue hemorrhagic fever, its incidence is increasing year by year, according to WHO statistics, more than 100 million people are infected with dengue virus every year, 500,000 people develop dengue hemorrhagic fever, and the annual death toll exceeds 25,000. At present, there are 2.5-3 billion people in the world living in dengue fever-affected areas and will be threatened by dengue virus infection. Local or imported outbreaks may occur in Guangdong, Hainan, Guangxi, Yunnan and Fujian provinces and regions in China at any time. Ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/577G01N33/569
CPCY02A50/30
Inventor 车小燕丘立文
Owner SOUTHERN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com